Progranulin and Breast Cancer Mortality: 13-Year Follow-Up of a Cohort Study

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Jung KW, Won YJ, Hong S, Kong HJ, Lee ES. Prediction of cancer incidence and mortality in Korea, 2020. Cancer Res Treat. 2020;52(2):351–358. doi:10.4143/crt.2020.203
   PubMed Web of Science ®Google Scholar
• DeSantis CE, Ma J, Gaudet MM, et al. Breast cancer statistics, 2019. CA. 2019;69(6):438–451. doi:10.3322/caac.21583
   Google Scholar
• Coates AS, Winer EP, Goldhirsch A, et al. Tailoring therapies--improving the management of early breast cancer: st Gallen International expert consensus on the primary therapy of early breast cancer 2015. Ann Oncol. 2015;26(8):1533–1546. doi:10.1093/annonc/mdv221
   PubMed Web of Science ®Google Scholar
• Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111–121. doi:10.1056/NEJMoa1804710
   PubMed Web of Science ®Google Scholar
• Pan H, Gray R, Braybrooke J, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377(19):1836–1846. doi:10.1056/NEJMoa1701830
   PubMed Web of Science ®Google Scholar
• Bae SY, Kim S, Lee JH, et al. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer. BMC Cancer. 2015;15(1):138. doi:10.1186/s12885-015-1121-4
   PubMedGoogle Scholar
• Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805–816. doi:10.1016/S0140-6736(12)61963-1
   PubMed Web of Science ®Google Scholar
• Goss PE, Ingle JN, Pritchard KI, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med. 2016;375(3):209–219. doi:10.1056/NEJMoa1604700
   PubMed Web of Science ®Google Scholar
• Serrero G. Autocrine growth factor revisited: PC-cell-derived growth factor (progranulin), a critical player in breast cancer tumorigenesis. Biochem Biophys Res Commun. 2003;308(3):409–413. doi:10.1016/S0006-291X(03)01452-9
   PubMed Web of Science ®Google Scholar
• Nguyen AD, Nguyen TA, Martens LH, Mitic LL, Farese RV Jr. Progranulin: at the interface of neurodegenerative and metabolic diseases. Trends Endocrinol Metab. 2013;24(12):597–606. doi:10.1016/j.tem.2013.08.003
   PubMed Web of Science ®Google Scholar
• Arechavaleta-Velasco F, Perez-Juarez CE, Gerton GL, Diaz-Cueto L. Progranulin and its biological effects in cancer. Med Oncol. 2017;34(12):194. doi:10.1007/s12032-017-1054-7
   PubMed Web of Science ®Google Scholar
• Koo DH, Park CY, Lee ES, Ro J, Oh SW. Progranulin as a prognostic biomarker for breast cancer recurrence in patients who had hormone receptor-positive tumors: a cohort study. PLoS One. 2012;7(6):e39880. doi:10.1371/journal.pone.0039880
   PubMed Web of Science ®Google Scholar
• Song YM, Sung J. Body mass index and mortality: a twelve-year prospective study in Korea. Epidemiology. 2001;12(2):173–179. doi:10.1097/00001648-200103000-00008
   PubMed Web of Science ®Google Scholar
• Youn BS, Bang SI, Kloting N, et al. Serum progranulin concentrations may be associated with macrophage infiltration into omental adipose tissue. Diabetes. 2009;58(3):627–636. doi:10.2337/db08-1147
   PubMed Web of Science ®Google Scholar
• Wells CA, Sloane JP, Coleman D, et al. Consistency of staining and reporting of oestrogen receptor immunocytochemistry within the European Union--an inter-laboratory study. Virchows Arch. 2004;445(2):119–128. doi:10.1007/s00428-004-1063-8
   PubMed Web of Science ®Google Scholar
• Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–752. doi:10.1038/35021093
   PubMed Web of Science ®Google Scholar
• Duffy MJ, Harbeck N, Nap M, et al. Clinical use of biomarkers in breast cancer: updated guidelines from the European Group on Tumor Markers (EGTM). Eur J Cancer. 2017;75:284–298. doi:10.1016/j.ejca.2017.01.017
   PubMed Web of Science ®Google Scholar
• Bateman A, Bennett HP. The granulin gene family: from cancer to dementia. BioEssays. 2009;31(11):1245–1254. doi:10.1002/bies.200900086
   PubMed Web of Science ®Google Scholar
• Abrhale T, Brodie A, Sabnis G, et al. GP88 (PC-cell derived growth factor, progranulin) stimulates proliferation and confers letrozole resistance to aromatase overexpressing breast cancer cells. BMC Cancer. 2011;11:231. doi:10.1186/1471-2407-11-231
   PubMed Web of Science ®Google Scholar
• Tangkeangsirisin W, Hayashi J, Serrero G. PC cell-derived growth factor mediates tamoxifen resistance and promotes tumor growth of human breast cancer cells. Cancer Res. 2004;64(5):1737–1743. doi:10.1158/0008-5472.CAN-03-2364
   PubMed Web of Science ®Google Scholar
• Tkaczuk KHR, Hawkins D, Yue B, Hicks D, Tait N, Serrero G. Association of serum progranulin levels with disease progression, therapy response and survival in patients with metastatic breast cancer. Clin Breast Cancer. 2020;20(3):220–227. doi:10.1016/j.clbc.2019.11.010
   PubMed Web of Science ®Google Scholar
• Guha R, Yue B, Dong J, Banerjee A, Serrero G. Anti-progranulin/GP88 antibody AG01 inhibits triple negative breast cancer cell proliferation and migration. Breast Cancer Res Treat. 2021;186(3):637–653. doi:10.1007/s10549-021-06120-y
   PubMed Web of Science ®Google Scholar
• Del Mastro L, Mansutti M, Bisagni G, et al. Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, Phase 3 trial. Lancet Oncol. 2021;22(10):1458–1467. doi:10.1016/S1470-2045(21)00352-1
   PubMed Web of Science ®Google Scholar
• Gnant M, Fitzal F, Rinnerthaler G, et al. Duration of adjuvant aromatase-inhibitor therapy in postmenopausal breast cancer. N Engl J Med. 2021;385(5):395–405. doi:10.1056/NEJMoa2104162
   PubMed Web of Science ®Google Scholar
• Goodwin PJ. Extended aromatase inhibitors in hormone-receptor-positive breast cancer. N Engl J Med. 2021;385(5):462–463. doi:10.1056/NEJMe2109356
   PubMed Web of Science ®Google Scholar
• Andre F, Ismaila N, Henry NL, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: ASCO clinical practice guideline update-integration of results from TAILORx. J Clin Oncol. 2019;37(22):1956–1964. doi:10.1200/JCO.19.00945
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update. J Clin Oncol. 2019;37(5):423–438. doi:10.1200/JCO.18.01160
   PubMed Web of Science ®Google Scholar